EPZ004777
SAM competitive inhibitor of DOT1L
Structure
In Cells
In Model Organisms
SERP ratings and comments
SERP Ratings
SERP Comments:
This DOT1L inhibitor was the first potent DOT1L ligand disclosed (by Epizyme) in 2011. EPZ004777 is an extremely potent and selective DOT1L inhibitor, making this an ideal probe for cellular use. The original publication shows that EPZ004777 effectively inhibits the proliferation of MLL-rearranged cell lines; however, due to restrictions of the pharmacokinetic properties of this molecule, whole animal studies needed to use subcutaneous osmotic pumps to attain useful compound exposure. Significant data on the non-epigenetic off-target profiling could not be found, and no closely related control compound is available.
(last updated: 21 Jan 2017 )
SERP Ratings
SERP Comments:
EPZ004777 is an excellent probe for cellular experiments. It specifically affected the MLL-translocated leukemia lines that are dependent on DOT1L recruitment and enzymatic function. Due to the PK limitationsof EPZ004777, EPZ-5676 would be the best choice of DOT1L in vivo probe.
(last updated: 28 Mar 2017 )
SERP Ratings
SERP Comments:
EPZ-5676, a derivative with a better pharmacokinetic profile than this probe, would be the better choice for a DOT1L chemical probe. EPZ-5676 is available commercially and is listed in the Portal. There are other derivatives which are better suited to in vivo model use.
(last updated: 27 Apr 2017 )